Liquidia Corporation

LQDA· NASDAQ· Health Care· Pharmaceuticals, Biotechnology & Life Sciences

$45.06+0.16%

2026-10-30

Financials

Valuation Metrics

Liquidia Corporation's Market Cap is $4.01B. At end of 2025 it was $3.00B. Ranked #1522 of 3,116 in US market (top 49%), #528 of 1,472 on NASDAQ (top 36%), #87 of 265 in Pharmaceuticals, Biotechnology & Life Sciences (top 33%) by Market Cap.

Investment Metrics(as of 2026-10-30)

Metric	Value	Rank
Size
Market Cap	$4.01B	US#1,522/3,116 Sec#87/265
Revenue	$451M	US#2,282/3,116 Sec#79/265
Net Income	$139M	US#1,476/3,116 Sec#50/265
Total Assets	$522M	US#2,740/3,116 Sec#158/265
Net Assets	$195M	US#2,677/3,116 Sec#192/265
Value
P/E	28.91x	US#1,533/3,116 Sec#41/265
P/B	20.54x	US#2,782/3,116 Sec#216/265
P/S	8.89x	US#2,646/3,116 Sec#109/265
EV/EBITDA	21.66x	US#1,955/3,116 Sec#51/265
FCF Yield	1.51%	US#2,097/3,116 Sec#70/265
Profitability
ROE	71.04%	US#66/3,116 Sec#6/265
ROA	26.56%	US#49/3,116 Sec#11/265
Op. Margin	37.39%	US#343/3,116 Sec#19/265
Revenue Growth	2233.65%	US#10/3,116 Sec#6/265
Financial Health
Debt Ratio	167.49%	US#1,609/3,116 Sec#189/265
Total Debt	$129M	US#2,361/3,116 Sec#107/265
FCF	$61M	US#1,910/3,116 Sec#68/265
Cash	$284M	US#1,454/3,116 Sec#83/265
Current Ratio	2.31x	US#1,060/3,116 Sec#210/265
Net Debt/EBITDA	-0.87x	US#310/3,116 Sec#20/265
Performance
1Y Return	94.22%	US#157/3,116 Sec#39/265
1M Return	48.91%	US#3,055/3,116 Sec#257/265
From 52W High	-51.86%	US#2,704/3,116 Sec#207/265
1Y MDD	-71.54%	US#2,951/3,116 Sec#236/265
Trading
Volume	2,072,365 shares	US#728/3,116 Sec#62/265
Trading Value	$94M	US#787/3,116 Sec#42/265
Per Share
EPS	$1.56	US#1,481/3,116 Sec#41/265
BPS	$2.19	US#2,555/3,116 Sec#173/265